Delving into the Latest Updates on UC-781 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

RT

Mechanism

RT inhibitors(Reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Chemtura Corp.

Active Organization-

Inactive Organization

Contraception Research and DevelopmentAdamisConrad AG

+ [1]

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC17H18ClNO2S

InChIKeyYZHIXLCGPOTQNB-UHFFFAOYSA-N

CAS Registry178870-32-1

This study is the first to try this product in the rectum of humans. This study is only to find out if the gel is safe for use in the rectum, not to see if the gel works. Information gathered from this study will help investigators decide whether this gel is safe enough to move onto the next phase of studies.
Information gathered from this study will also help investigators determine what participants did and did not like about the product and what types of products people might want to use in the future. Currently condoms and abstinence are the only methods proven to prevent the spread of HIV sexually.

Start Date01 Dec 2006

Sponsor / Collaborator

University of California, Los Angeles

[+2]

NCT00441909 / CompletedPhase 1IIT

Phase I Study of the Safety and Persistence of 0.1% UC-781 Vaginal Gel in HIV-1 Seronegative Women

Vaginal microbicides are compounds that may protect women from HIV and other sexually transmitted infections (STIs). This study will determine the safety of the microbicide UC-781 by comparing the effects of keeping the microbicide in the vagina for different lengths of time.

Start Date01 Apr 2006

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

100 Clinical Results associated with UC-781

Login to view more data

100 Translational Medicine associated with UC-781

Login to view more data

100 Patents (Medical) associated with UC-781

Login to view more data

99

Literatures (Medical) associated with UC-781

24 Apr 2016·AIDSQ2 · MEDICINE

Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates

Q2 · MEDICINE

Article

Author: Alcami, Jose ; Shattock, Robin J. ; Armanasco, Naomi ; Garcia-Perez, Javier ; Ziprin, Paul ; Nuttall, Jeremy ; Olejniczak, Natalia ; Herrera, Carolina

OBJECTIVEReceptive anal intercourse in both men and women is associated with the highest probability for sexual acquisition of HIV infection. As part of a program to develop an effective prevention strategy, we performed an ex-vivo preclinical evaluation to determine the efficacy of multiple double combinations of maraviroc (MVC) and reverse transcriptase inhibitors (RTIs).DESIGNThe entry inhibitor, MVC, a nucleotide RTI, tenofovir and two non-nucleoside RTIs, UC781 and TMC120 (dapivirine, DPV), were used in double, combinations against a panel of CCR5-using clade B and clade C HIV-1 isolates and against MVC-escape variants. A gel-formulated version of MVC-DPV combination was also tested.METHODSIndicator cells, cocultures of immature dendritic cells with CD4T cells, and colorectal tissue explants were used to assess antiviral activity of drug combinations.RESULTSAll dual MVC-RTI combinations tested inhibited MVC-sensitive and resistant isolates in cellular and colorectal explants models. All the combinations were positive with no reduction in the activity of MVC. In tissue explants, the combinations against all viral isolates tested produced an increase in the activity of MVC. An initial gel-formulation of MVC-DPV combination showed greater and prolonged antiviral activity of MVC in mucosal tissue explants.CONCLUSIONThis study demonstrates that combinations based on antiretroviral drugs inhibiting HIV transmission at viral entry and reverse transcription have potential as prevention strategies against colorectal transmission of HIV-1 including MVC-resistant isolates. Preclinical evaluation with colorectal tissue explants indicates that a gel-formulation of MVC-DPV is an effective candidate colorectal microbicide.

01 Sep 2015·ContraceptionQ2 · MEDICINE

Assessing the potential of the Woman’s Condom for vaginal drug delivery

Q2 · MEDICINE

Article

Author: Dezzutti, Charlene S ; Kramzer, Lindsay F ; Friend, David ; Schubert, Jesse ; Rohan, Lisa C ; Moncla, Bernard J ; Cohen, Jessica

BACKGROUNDThe Woman's Condom is a new female condom that uses a dissolvable polyvinyl alcohol capsule to simplify vaginal insertion. This preclinical study assessed the feasibility to incorporate an antiviral drug, UC781, into the Woman's Condom capsule, offering a unique drug delivery platform.STUDY DESIGNUC781 capsules were fabricated using methods from the development of the Woman's Condom capsules as well as those used in vaginal film development. Capsules were characterized to evaluate physical/chemical attributes, Lactobacillus compatibility, in vitro safety and bioactivity, and condom compatibility.RESULTSTwo UC781 capsule platforms were assessed. Capsule masses (mg; mean±SD) for platforms 1 and 2 were 116.50±18.22 and 93.80±8.49, respectively. Thicknesses were 0.0034±0.0004 in and 0.0033±0.0004 in. Disintegration times were 11±3 s and 5±1 s. Puncture strengths were 21.72±3.30 N and 4.02±0.83 N. Water content measured 6.98±1.17% and 7.04±1.92%. UC781 content was 0.59±0.05 mg and 0.77±0.11 mg. Both platforms retained in vitro bioactivity and were nontoxic to TZM-bl cells and Lactobacillus. Short-term storage of UC781 capsules with the Woman's Condom pouch did not decrease condom mechanical integrity.CONCLUSIONSUC781 was loaded into a polymeric capsule similar to that of the Woman's Condom product. This study highlights the potential use of the Woman's Condom as a platform for vaginal delivery of drugs relevant to sexual/reproductive health, including those for short- or long-acting HIV prevention.IMPLICATIONSWe determined the proof-of-concept feasibility of incorporation of an HIV-preventative microbicide into the Woman's Condom capsule. This study highlights various in vitro physical and chemical evaluations as well as bioactivity and safety assessments necessary for vaginal product development related to female sexual and reproductive health.

01 Feb 2015·Drug Delivery and Translational ResearchQ3 · MEDICINE

Lack of in vitro–in vivo correlation for a UC781-releasing vaginal ring in macaques

Q3 · MEDICINE

Article

Author: Ron A. Otten ; R. Karl Malcolm ; Christopher McConville ; Priya Srinivasan ; Clare F. McCoy ; Angela Holder ; James M. Smith ; David R. Friend ; Gustavo F. Doncel ; Salvatore Butera ; James Mitchell

This study describes the preclinical development of a matrix-type silicone elastomer vaginal ring device designed to provide controlled release of UC781, a non-nucleoside reverse transcriptase inhibitor. Testing of both human- and macaque-sized rings in a sink condition in vitro release model demonstrated continuous UC781 release in quantities considered sufficient to maintain vaginal fluid concentrations at levels 82-860-fold higher than the in vitro IC50 (2.0 to 10.4 nM) and therefore potentially protect against mucosal transmission of HIV. The 100-mg UC781 rings were well tolerated in pig-tailed macaques, did not induce local inflammation as determined by cytokine analysis and maintained median concentrations in vaginal fluids of UC781 in the range of 0.27 to 5.18 mM during the course of the 28-day study. Analysis of residual UC781 content in rings after completion of both the in vitro release and macaque pharmacokinetic studies revealed that 57 and 5 mg of UC781 was released, respectively. The pharmacokinetic analysis of a 100-mg UC781 vaginal ring in pig-tailed macaques showed poor in vivo-in vitro correlation, attributed to the very poor solubility of UC781 in vaginal fluid and resulting in a dissolution-controlled drug release mechanism rather than the expected diffusion-controlled mechanism.

100 Deals associated with UC-781

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05871

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	-	Adamis	-
HIV Infections	Phase 2	-	Adamis	-
HIV Infections	Phase 2	-	Chemtura Corp.	-
HIV Infections	Phase 2	-	Chemtura Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2006	Not Applicable	HIV Infections	-	UC781	ozxftxopzz(ealbsiccdq) = hbtsygdlas zwgrtuxbew (vqlmevfkgo )	-	01 Jan 2006
IAS2001	Not Applicable	HIV Infections	-	UC781	etlensofzb(ewsntqavzz) = ljtqrfzrri jzkjubqjpy (zvhkzbkpaq )	-	01 Jan 2001